SELP and neoplasm: Some clinical studies found high P-selectin levels in cancer patients, with or without correlation to tumor clinical advancement [97,112]; conversely, recent observational and longitudinal studies enrolling patients with heterogeneous cancers found a decrease in platelet surface expression of this protein, which, together with diminished integrin αIIbβ3 exposure, thrombin and collagen receptor responsiveness and monocyte–platelet aggregate formation, correlates with risk of mortality and VTE [113,114].